Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vaccitech stock | $14.57

Learn how to easily invest in Vaccitech stock.

Vaccitech plc is a biotechnology business based in the US. Vaccitech shares (VACC) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccitech employs 48 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Vaccitech

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VACC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vaccitech stock price (NASDAQ: VACC)

Use our graph to track the performance of VACC stocks over time.

Vaccitech shares at a glance

Information last updated 2021-10-17.
Latest market close$14.57
52-week range$12.25 - $17.99
50-day moving average $15.31
200-day moving average $15.02
Wall St. target price$24.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-9.52

Buy Vaccitech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vaccitech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaccitech price performance over time

Historical closes compared with the close of $14.57 from 2021-10-20

1 week (2021-10-15) -0.48%
1 month (2021-09-22) -8.42%
3 months (2021-07-22) -1.29%
6 months (2021-04-18) N/A
1 year (2020-10-18) N/A
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Vaccitech financials

Revenue TTM $3.9 million
Gross profit TTM $-9,566,249
Return on assets TTM -30.07%
Return on equity TTM -420.06%
Profit margin 0%
Book value $7.27
Market capitalisation $502.6 million

TTM: trailing 12 months

Shorting Vaccitech shares

There are currently 65,318 Vaccitech shares held short by investors – that's known as Vaccitech's "short interest". This figure is 29.2% up from 50,544 last month.

There are a few different ways that this level of interest in shorting Vaccitech shares can be evaluated.

Vaccitech's "short interest ratio" (SIR)

Vaccitech's "short interest ratio" (SIR) is the quantity of Vaccitech shares currently shorted divided by the average quantity of Vaccitech shares traded daily (recently around 16494.444444444). Vaccitech's SIR currently stands at 3.96. In other words for every 100,000 Vaccitech shares traded daily on the market, roughly 3960 shares are currently held short.

To gain some more context, you can compare Vaccitech's short interest ratio against those of similar companies.

However Vaccitech's short interest can also be evaluated against the total number of Vaccitech shares, or, against the total number of tradable Vaccitech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccitech's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Vaccitech shares in existence, roughly 0 shares are currently held short) or 0.0029% of the tradable shares (for every 100,000 tradable Vaccitech shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccitech.

Find out more about how you can short Vaccitech stock.

Vaccitech share dividends

We're not expecting Vaccitech to pay a dividend over the next 12 months.

Vaccitech overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection; VTP-200 for the treatment of human papilloma virus infection; VTP-850 indicated for the treatment of prostate cancer; and VTP-600 for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. .

Frequently asked questions

What percentage of Vaccitech is owned by insiders or institutions?
Currently 29.791% of Vaccitech shares are held by insiders and 10.011% by institutions.
How many people work for Vaccitech?
Latest data suggests 48 work at Vaccitech.
When does the fiscal year end for Vaccitech?
Vaccitech's fiscal year ends in December.
Where is Vaccitech based?
Vaccitech's address is: The Schrödinger Building, Oxford, United Kingdom, OX4 4GE
What is Vaccitech's ISIN number?
Vaccitech's international securities identification number is: US91864C1071

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site